(#37) Exploration of Negative Symptoms and Digital Application Use in People with Schizophrenia

Abstract: Background: Negative symptoms of schizophrenia (NS) profoundly impact functional outcomes. As there are currently no approved pharmacotherapies for NS, innovative treatments are needed. This study investigated the potential of prescription digital therapeutics (PDTs) for NS from the perspectives of those living with schizophrenia, focusing on their experience/conceptualization of NS, and patterns/preferences of smartphone app use. Methods: People with schizophrenia recruited through a US-based non-profit schizophrenia advocacy organization (n=49) completed a survey; 29/49 respondents participated in a 90-minute focus group (n=26) or individual interview (n=3). Anonymized transcripts were coded using a hybrid analytic approach. Results: Survey participantsí mean (range) age was 42 (21ñ71) years; 49% were women, 61% White, and 16% Hispanic. Overall, 94% used smartphones and 39% used mental health apps. Focus group participants had difficulty defining NS; once defined, NS were described as profoundly challenging across multiple life domains. Seventy-nine percent reported that it is very/extremely important to treat NS. Participants reported trying different coping skills (e.g., mindfulness), but reported a need for more effective strategies. Regarding health apps, participants expressed preference for ease of log-in/use, interactivity, therapist integration, and being informative and positive. Participants expressed dislike of apps being complicated, costly, or sending too many reminders. Participants were open to a theoretical PDT, and would like help with symptoms, education, independence, daily living skills, and setting goals related to social interactions. Conclusions: NS were self-reported as common and detrimental to quality of life. PDTs hold promise as novel, scalable therapies for NS. Funding: Boehringer Ingelheim Pharmaceuticals, Inc.Short Description: This study investigated the potential of prescription digital therapeutics for negative symptoms of schizophrenia from the perspectives of people living with schizophrenia. Insights were gathered using a survey, focus groups, and individual interviews. Negative symptoms were self-reported as common and detrimental to quality of life, and participants were open to a theoretical prescription digital therapeutic to help with symptoms, education, independence, and daily living skills, and to set goals related to social interactions.Name of Sponsoring Organization(s): Boehringer Ingelheim Pharmaceuticals, Inc.